Such genomic advances have also allowed the recognition of broader clinical phenotypes associated with SLC6A3, encompassing DTDS parkinsonism-dystonia, early onset parkinsonism, and neuropsychiatric diseases (ADHD and ASD). The gene discussed is SLC6A3; the disease is attention deficit-hyperactivity disorder.